Pfenex to Regain Full Rights to PF582

News   Aug 09, 2016

 
Pfenex to Regain Full Rights to PF582
 
 
 

RELATED ARTICLES

170 Potential Lung Cancer Drug Targets Identified Using Unique Cellular Library

News

After testing more than 200,000 chemical compounds, UT Southwestern’s Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

READ MORE

Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening

News

A multidisciplinary team of scientists share recent advancements in innovative in-vitro cancer biology methods for screening drug-like molecules in cancer tissue relevant models in a new report published online ahead-of-print at SLAS Discovery.

READ MORE

PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets

News

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE